# Evidence-Based Dietary Patterns ## 5:2 Intermittent Fasting Meal Replacement - **Description**: Alternate 2 nonconsecutive days of severe restriction (500 kcal women/600 kcal men via meal replacements) with 5 days of normal eating (dinner replaced by meal replacement; balanced breakfast/lunch). - **Evidence**: In RCTs, reduces HbA1c by 1.9% and weight by 9.7 kg over 16 weeks; 80% achieve HbA1c <6.5%. Benefits persist 8 weeks post-intervention. - **Suitability**: Adults 18–65 with new T2D (≤1 year), BMI ≥24, HbA1c 7–9%, no recent meds. Ideal for motivated patients preferring structured regimens. - **Safety/Monitoring**: Avoid in eating disorders, underweight, or meds needing meal timing. Monitor adherence to prevent deficiencies; nutritional risks low with replacements. ## Mediterranean Diet - **Description**: High fruits/veggies/whole grains/legumes/nuts/olive oil; moderate fish/poultry; low red/processed meats; optional moderate wine. - **Evidence**: PREDIMED RCT shows 30% CVD risk reduction over 4.8 years; meta-analyses: HbA1c ↓0.3–0.4%, weight ↓0.3–1 kg; improves BP, lipids, inflammation. - **Suitability**: Adults with/at risk for T2D, metabolic syndrome, CVD. Adaptable culturally; use with/without calorie limits for weight goals. - **Safety/Monitoring**: Safe for most; monitor potassium in advanced CKD. High adherence with support. ## DASH Diet - **Description**: High fruits/veggies/low-fat dairy/whole grains/nuts/legumes; low saturated fat/cholesterol/sodium (1,500–2,400 mg/day). - **Evidence**: RCTs: SBP ↓5.2 mmHg, DBP ↓2.6 mmHg, HbA1c ↓0.53%, weight ↓1.4–1.6 kg over 8–12 weeks. DASH4D variant enhances glycemic control. - **Suitability**: Patients with hypertension, T2D, CVD risk (AHA/ADA recommended). Improve adherence with substitutions like frozen produce/plant milks. - **Safety/Monitoring**: Safe generally; caution for hyperkalemia in advanced CKD. Moderate adherence; behavioral support helps. ## Low-Carbohydrate Diets (LCD/VLCD) - **Description**: LCD: <130 g carbs/day (<26% energy); VLCD: <50 g/day (<10% energy); focus on proteins/fats/veggies. - **Evidence**: Meta-analyses: HbA1c ↓0.4–0.6% (LCD)/0.6–1.3% (VLCD) at 3–6 months; weight ↓3–14 kg; TG ↓, HDL ↑; LDL may rise transiently. - **Suitability**: T2D, metabolic syndrome (ADA/AACE options). Best short-term; long-term adherence challenging, benefits fade at 12 months. - **Safety/Monitoring**: Medically supervised; adjust insulin/sulfonylureas for hypoglycemia risk. Monitor glycemia, lipids, meds regularly. ## Plant-Based Diets - **Description**: Vegetarian/vegan: whole plant foods; minimal/no animal products. Ensure B12/iron/calcium/omega-3 adequacy. - **Evidence**: HbA1c ↓0.5–1.0%; 20–30% lower T2D progression; improves weight/BP/lipids. - **Suitability**: Motivated patients with/at risk for T2D. Adaptable culturally/economically. - **Safety/Monitoring**: Supplement deficiencies (esp. vegan); safe for most. ## Time-Restricted Eating (TRE/eTRF) - **Description**: TRE: 8–10 hour eating window daily; eTRF: meals earlier (circadian-aligned). - **Evidence**: RCTs: weight ↓1.6–3.7 kg, fat ↓1.5–2.8 kg, HbA1c ↓0.1–0.2%; boosts insulin sensitivity/BP/lipids. High adherence (70–94%). - **Suitability**: Metabolic syndrome/prediabetes/obesity. Combine with other diets. - **Safety/Monitoring**: Mild/transient effects; monitor/adjust insulin/sulfonylureas for hypoglycemia. ## Timing of Unsaturated Fat Intake - **Description**: Advance unsaturated fats (mono/poly from oils) to lunch in isocaloric diet (energy: 25% breakfast/40% lunch/35% dinner); meals in 30 min; no alcohol/caffeine. - **Evidence**: Reduces postprandial insulin by 50%, improves sensitivity by 20% via microbiome/bile acids. - **Suitability**: Insulin resistance; integrate into Mediterranean/DASH. - **Safety/Monitoring**: Safe; monitor gut changes. # Quantitative Outcomes and Comparative Efficacy The following summary table provides a quantitative comparison for the major dietary patterns discussed. | Dietary Pattern / Protocol | HbA1c Reduction | Weight Loss | CV Event Reduction | Other Key Outcomes | | ----------------------------------------- | ----------------- | ------------------------- | ----------------------------- | --------------------------------------------------------------------- | | 5:2 Intermittent Fasting Meal Replacement | 1.9% (16 wks) | 9.7 kg (16 wks) | Not reported | 80% achieve HbA1c <6.5% at 16 wks; benefits persist at 8-wk follow-up | | Mediterranean Diet | 0.30–0.39% | 0.3–1.0 kg | 30% (4.8 yrs) | ↓ BP (1–2 mmHg), ↓ LDL, ↑ HDL, ↓ TG, ↓ inflammation | | DASH Diet | 0.53% | 1.4–1.6 kg | 20% (cohort data) | ↓ SBP/DBP (5.2/2.6 mmHg), ↓ LDL, ↑ HDL, ↓ TG | | Low-Carbohydrate Diet (<130g/d) | 0.4–0.6% (3–6 mo) | 3–7.5 kg (3–6 mo) | Not reported | ↑ HDL, ↓ TG, ↓ BP, effect attenuates at 12 mo | | Very Low-Carbohydrate Diet (<50g/d) | 0.6–1.3% (3–6 mo) | 12–14 kg (high adherence) | Not reported | Possible ↑ LDL, higher dropout, effect attenuates at 12 mo | | Plant-Based Diet | 0.5–1.0% | 2–5 kg | 20–30% ↓ diabetes progression | ↓ BP, ↓ LDL, ↑ HDL, requires B12/iron/Ca monitoring | | Time-Restricted Eating (8–10h window) | 0.1–0.2% | 1.6–3.7 kg | Not reported | ↓ fat mass, ↑ insulin sensitivity, ↓ BP, high adherence |